SubHero Banner

Absorica® LD (isotretinoin) – New formulation approval

November 5, 2019 - The FDA approved Sun Pharmaceuticals’ Absorica LD (isotretinoin) capsules, for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, Absorica LD is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.

Download PDF